Beijing SL Pharmaceutical Co., Ltd.

Symbol: 002038.SZ

SHZ

9.38

CNY

company-market-status

  • 25.4552

    P/E ratio

  • 1.8328

    PEG ratio

  • 9.64B

    Mrk Cap

  • 0.01%

    Div Yield

Акции в обращение

1027.350016M

Притежавани от вътрешни лица

0.011%

Притежавани от институции

1.072%

  • Highest
    • 33.89
    • 30.65
    • 27.07
    • 23.65
    • 22.36
    • 26.16
    • 27.02
    • 23.88
    • 23.30
    • 13.55
    • 12.04
    • 12.62
    • 12.69
    • 11.57
    • 10.75
    • 11.30
    • 12.48
    • 12.48
    • 11.43
    • 11.46
    • 9.90
    • 8.58
    • 9.23
    • 9.91
    • 11.70
    • 10.72
    • 9.75
    • 9.25
    • 10.54
    • 9.67
    • 10.31
    • 10.55
    • 9.75
    • 9.76
    • 9.70
    • 9.06
    • 8.56
    • 8.96
    • 8.72
    • 9.07
    • 9.48
  • Lowest
    • 32.94
    • 30.65
    • 26.02
    • 23.65
    • 21.49
    • 25.41
    • 26.37
    • 23.88
    • 22.80
    • 13.40
    • 12.04
    • 12.38
    • 12.69
    • 11.34
    • 10.75
    • 10.98
    • 12.13
    • 12.26
    • 11.43
    • 11.12
    • 9.90
    • 8.24
    • 9.08
    • 9.23
    • 11.32
    • 10.32
    • 9.56
    • 9.05
    • 10.33
    • 9.67
    • 10.18
    • 10.30
    • 9.59
    • 9.61
    • 9.48
    • 8.95
    • 8.24
    • 8.75
    • 8.60
    • 8.93
    • 9.32

Информация за компанията

Последващ PE: Healthcare
Индустрия: Drug Manufacturers—Specialty & Generic
ГЛАВЕН ИЗПЪЛНИТЕЛЕН ДИРЕКТОР:Dr. Mingbo Xu
Служители на пълно работно време:757
Град:Beijing
Адрес:Building 1, Bitongyuan
IPO:2004-09-09
CIK:

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.

Оборотен капитал

202220212020201920182017
Парични средства и инвестиции595.04827.84663.481260.861166.201438.81
Приемници0.000.000.000.000.000.00
Инвентарна книга136.82124.83112.03108.35251.27275.70
Други714.51648.74608.08514.441356.041268.24
Общо текущи активи1997.672297.732207.342865.342803.163053.05
Acc Payable176.18191.40179.93178.51264.95111.50
Краткосрочен дълг0.000.255.513.940.000.00
Други текущи пасиви112.65133.31129.54150.19124.5773.05
Текущи пасиви288.83324.96314.98332.63440.52249.67

Капиталова структура

Всички числа в милиони

Общо активи

102,84 щ.д.

Общо задължения

17228527,11 щ.д.

Дългосрочен дълг

0,00 щ.д.

Парични средства и екви

11715241,37 щ.д.

Goodwill

0,00 щ.д.

Неразпределена печалба

37709136,74 щ.д.

Обикновени акции

1027,35 щ.д.

Стойност на предприятието

45,81 щ.д.

Дивиденти за маса

ГодиниQ1Q2Q3Q4Общо
20050.0000.0140.0000.0000.014
20060.0000.0080.0000.0000.008
20070.0000.0130.0000.0000.013
20080.0000.0120.0000.0000.012
20090.0000.0490.0000.0000.049
20100.0000.0490.0000.0000.049
20110.0000.0620.0000.0000.062
20120.0000.0000.0740.0000.074
20130.0000.0930.0000.0000.093
20140.0000.0000.0890.0000.089
20150.0000.0000.1330.0000.133
20160.0000.0000.1330.0000.133
20170.0000.0000.1330.0000.133
20180.0000.3330.0000.0000.333
20190.0000.0000.2000.0000.200
20200.0000.0000.2000.0000.200
20210.0000.0000.1000.0000.100
20220.0000.1000.0000.0000.100
Подобни запаси
Може да се интересувате и от
PILL.CN
Canntab Therapeutics Limited.
0.015 CAD
CNQ
CRON
Cronos Group Inc..
1.75 USD
NASDAQ
RMTI
Rockwell Medical, Inc..
3.32 USD
NASDAQ
ATNX
Athenex, Inc..
0.2031 USD
NASDAQ
SCYX
SCYNEXIS, Inc..
2.62 USD
NASDAQ
RDHL
RedHill Biopharma Ltd..
2.2 USD
NASDAQ
CPIX
Cumberland Pharmaceuticals Inc..
1.61 USD
NASDAQ
PRPH
ProPhase Labs, Inc..
9.15 USD
NASDAQ
OGI
OrganiGram Holdings Inc..
0.39 USD
NASDAQ
BOI.PA
Boiron SA.
37.15 EUR
EURONEXT

Frequently Asked Question

Why is your stock tool better than competitors?

Numfin provides most features for free and gives you accurate and expert data about public companies. We also offer unique features like AI copilot that are not found on other platforms

Can I trust the data on your website and where do they come from?

Absolutely. We receive the data from our partners and other official sources, such as popular stock exchanges (NASDAQ, NYSE, and others), SEC.gov, and other official platforms. Our data provider, FinancialModeling, also provides information for portals like Moody's, Harvard, Chevron, and others. All this proves the accuracy and authority of the information.

Who creates the content on your website and is it approved by experts in finance and investing?

All financial data is received from our data provider and then verified by industry experts. Additionally, we use various AI tools like ChatGPT to present content in a user-friendly and well-structured manner.

What problem does your tool solve? Who is the target audience for your tool

Our main goal is to present accurate and expert information about public companies in a structured manner. We work with investors and financial professionals who have a long-term outlook. Our community consists of private investors, business owners, stock analysts, fund managers, and people who are interested in investing.

Why did you decide to create your tool?

While managing our own money, we searched for the best analytical tool to help us better analyze public companies. Most websites that provided analytics for professional investors were expensive, and the cheap tools were either limited in functionality or lacked valuable company data. Even worse, some of them presented incorrect numbers. As a result, we combined our experience in business, IT, and finance to create the most affordable and useful solution for investors and anyone interested in finance and stock analysis.

What is the difference between free and paid options? Should I buy Pro version from start or it's ok to have a free version?

Most features on our website are free so that many people can use it to analyze companies on the world's top stock exchanges. However, some features, such as our artificial intelligence chat, advanced analytics, filters, and storing of vast historical data, require additional servers from our end. Therefore, we rely on your support to keep this amazing project running. If you would like to experience the full potential of our service, we strongly recommend that you purchase the PRO version, which comes with a 30-day money-back guarantee

Who is your team and do they have enough experience?

You can read about our team here, or you can contact us at [email protected] for more information.